AG
MACK

Advisor Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Advisor Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-127
Closed -$1K – 5082
2017
Q2 		$1K Hold
127
– – ﹤0.01% 4753
2017
Q1 		$3K Buy
+127
New +$3.18K ﹤0.01% 4343

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisor Group's MACK Position: Q3 2017 in Review

Advisor Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 127 shares — an estimated $1K sold.

Advisor Group first reported a position in MACK in Q1 2017 and held it in 2 quarters. The position peaked at $3K in Q1 2017. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Advisor Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Advisor Group sold 127 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1K.
  • Advisor Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • Advisor Group's Merrimack Pharmaceuticals, Inc. position peaked at $3K in Q1 2017.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Advisor Group's 13F filing for Q3 2017, filed 6 Nov 2017.